Evidence map›Paper›PMID 41725020›Full record

Trial reportStem cell research & therapy2026

Safety and feasibility of intravenous fresh adipose-derived mesenchymal stem cells in secondary progressive multiple sclerosis: phase I/IIa clinical results.

Fahimeh Lavi Arab, Forouzan Yousefi, Hojjat Naderi-Meshkin, Mahdi Mirahmadi, Fatemeh Faraji, Karim Nikkhah, Houshang Amiri, Marjan Erfani, Fatemeh Ayoobi, Nafiseh Sadat Tabasi and 2 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fahimeh Lavi ArabImmunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. fahime.lavi@gmail.com.
Forouzan YousefiImmunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hojjat Naderi-MeshkinStem Cell and Regenerative Medicine Research Group, Academic Center for Education, Culture, and Research (ACECR), Khorasan Razavi Branch, Mashhad, Iran.
Mahdi MirahmadiStem Cell and Regenerative Medicine Research Group, Academic Center for Education, Culture, and Research (ACECR), Khorasan Razavi Branch, Mashhad, Iran.
Fatemeh FarajiImmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
Karim NikkhahDepartment of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Houshang AmiriNeuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Marjan ErfaniDepartment of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Fatemeh AyoobiOccupational Safety and Health Research Center, NICICO, World Safety Organization, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Nafiseh Sadat TabasiDepartment of Immunology and Allergy, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ali NikkhahMental Health Services for Elderly, St. Davnet's Campus, Health Service Executive, Monaghan, Ireland.
Mahmoud MahmoudiImmunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. MahmoudiM@mums.ac.ir.

Funding

Mashhad University of Medical Sciences 921082
6 · The paper itself

Abstract

objectiveMesenchymal stem cells (MSCs) hold substantial promise in regenerative medicine owing to their immunomodulatory, neuroregenerative, and self-renewal properties. Adipose tissue (AT) serves as an optimal MSC source due to its high yield and rapid proliferation. This study evaluated the safety and exploratory clinical effects of non-cryopreserved, culture-expanded autologous AT-MSCs in patients with secondary progressive multiple sclerosis (SPMS).

methodsHigh-dose fresh autologous AT-MSCs (4.4 × 10

resultsNo serious adverse events occurred over 9 months. AT-MSC therapy reduced T2-FLAIR lesion number and volume, improved EDSS scores, and enhanced psychological outcomes. It also increased Treg cell proportions and anti-inflammatory cytokine expression while decreasing inflammatory cytokines.

conclusionHigh-dose fresh AT-MSCs appear safe and well-tolerated in SPMS patients, with promising exploratory clinical benefits. These findings support AT-MSCs as a potential multiple sclerosis therapy. Trial registration Registered with the Iranian Registry of Clinical Trials (Reference: IRCT20091127002778N1 at 2018-01-10).

Indexed as

Adipose TissueMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMultiple Sclerosis, Chronic ProgressiveAdultFemaleHumansMagnetic Resonance ImagingMiddle AgedQuality of LifeAT-MSCsClinical trialCulture-expanded adipose tissue mesenchymal stem cellsMSNon-cryopreservedSecondary progressive multiple sclerosisSPMS

Identifiers

PMID41725020
PMCPMC13032625

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.